Redx Pharma Plc demonstrates control of operating expenses in H1FY20

  • Jun 30, 2020 BST
  • Team Kalkine
Redx Pharma Plc demonstrates control of operating expenses in H1FY20


Redx Pharma Plc (LON: REDX) has released its results for the six months ended 31 March 2020.

  • The company has demonstrated control of operating expenses £5.2 million as compared to £5.0 million in H1 2019.
  • The loss for the period was of £4 million as compared to £2.3 million in H1 2019.
  • The company reported that Redmile Group LLC provided funding to the company, comprising an initial equity investment of £1.3 million in March, followed by £5 million of short-term debt funding in April.
  • On 30th June 2020, at the time of writing, GMT 08:58 AM, REDX shares were trading at GBX 18.50, up by 1.00 points or 5.71% against the previous day closing price.


The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site.


With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK